Skip to main content
SpringerLink
Log in

Colon cancer 12-gene assay cost saving in the US

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Alberts SR, et al. Comparative Economics of a 12-Gene Assay for Predicting Risk of Recurrence in Stage II Colon Cancer. PharmacoEconomics : 26 Aug 2014. Available from: URL: http://doi.org/10.1007/s40273-014-0207-1

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Colon cancer 12-gene assay cost saving in the US. PharmacoEcon Outcomes News 712, 11 (2014). https://doi.org/10.1007/s40274-014-1556-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1556-x

Search

Navigation